Boston Scientific (BSX) Revenue — Quarter Ended Mar 31, 2024
Revenue increased in the current quarter compared to both the immediately preceding quarter and the same quarter one year earlier. The growth was supported by higher sales across the company's segments.
Key takeaway
Quarter ended Mar 31, 2024 · FY2024 Q1
Revenue increased in the current quarter compared to both the immediately preceding quarter and the same quarter one year earlier. The growth was supported by higher sales across the company's segments.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$3.9B
Revenue reported for this quarter.
Quarter-over-quarter
+3.5%
Change from the immediately preceding quarter.
Year-over-year
+13.8%
Change from the comparable year-ago quarter.
Trailing four quarters
$14.7B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Jun 30, 2023 | $3.6B | +10.9% |
| Sep 30, 2023 | $3.5B | +11.3% |
| Dec 31, 2023 | $3.7B | +14.9% |
| Mar 31, 2024 | $3.9B | +13.8% |
Revenue performance
The sequential increase continued a trend of rising revenue over recent quarters. The year-over-year gain reflected broad-based strength in the business.
Quarterly comparison
Compared to the prior quarter, revenue was higher, and versus the same quarter last year, revenue also increased, with contributions from both the MedSurg and Cardiovascular segments.
What to watch
Foreign currency exchange rates had a negative impact on reported revenue growth during the quarter, which may warrant attention in future periods.